Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dependovirus | 24 | 2025 | 709 | 3.330 |
Why?
|
| Genetic Vectors | 22 | 2025 | 879 | 3.030 |
Why?
|
| Genetic Therapy | 27 | 2025 | 791 | 3.010 |
Why?
|
| Tay-Sachs Disease | 6 | 2025 | 46 | 2.310 |
Why?
|
| Sandhoff Disease | 11 | 2025 | 36 | 1.950 |
Why?
|
| Sheep | 9 | 2025 | 179 | 1.690 |
Why?
|
| Central Nervous System | 11 | 2024 | 197 | 1.260 |
Why?
|
| Brain | 13 | 2025 | 1556 | 1.210 |
Why?
|
| Disease Models, Animal | 18 | 2025 | 2183 | 1.180 |
Why?
|
| Gangliosidosis, GM1 | 4 | 2025 | 19 | 1.140 |
Why?
|
| Cats | 19 | 2024 | 87 | 1.080 |
Why?
|
| Transduction, Genetic | 6 | 2021 | 237 | 0.990 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2025 | 2173 | 0.930 |
Why?
|
| Cerebellopontine Angle | 1 | 2024 | 8 | 0.900 |
Why?
|
| Cisterna Magna | 2 | 2024 | 15 | 0.860 |
Why?
|
| Gene Transfer Techniques | 6 | 2024 | 321 | 0.850 |
Why?
|
| Gangliosidoses, GM2 | 4 | 2025 | 19 | 0.830 |
Why?
|
| Huntington Disease | 2 | 2022 | 154 | 0.800 |
Why?
|
| Green Fluorescent Proteins | 1 | 2024 | 366 | 0.800 |
Why?
|
| Animals | 40 | 2025 | 20641 | 0.770 |
Why?
|
| beta-N-Acetylhexosaminidases | 6 | 2020 | 20 | 0.710 |
Why?
|
| Gene Expression | 4 | 2020 | 840 | 0.690 |
Why?
|
| White Matter | 1 | 2022 | 123 | 0.670 |
Why?
|
| Injections | 1 | 2020 | 81 | 0.660 |
Why?
|
| Thalamus | 1 | 2020 | 73 | 0.630 |
Why?
|
| beta-Hexosaminidase alpha Chain | 2 | 2025 | 14 | 0.620 |
Why?
|
| beta-Hexosaminidase beta Chain | 1 | 2017 | 2 | 0.560 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 289 | 0.510 |
Why?
|
| Biomarkers | 4 | 2023 | 1405 | 0.500 |
Why?
|
| Tissue Distribution | 4 | 2024 | 292 | 0.480 |
Why?
|
| Cat Diseases | 3 | 2023 | 17 | 0.480 |
Why?
|
| Capsid Proteins | 3 | 2021 | 101 | 0.400 |
Why?
|
| Transgenes | 4 | 2022 | 187 | 0.400 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2024 | 144 | 0.370 |
Why?
|
| Neurodegenerative Diseases | 2 | 2023 | 143 | 0.340 |
Why?
|
| Humans | 25 | 2025 | 63437 | 0.320 |
Why?
|
| Phenotype | 2 | 2024 | 1207 | 0.260 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2025 | 14 | 0.240 |
Why?
|
| Lysophospholipids | 1 | 2025 | 26 | 0.240 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 24 | 0.240 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2025 | 9 | 0.230 |
Why?
|
| G(M2) Activator Protein | 1 | 2024 | 2 | 0.230 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2025 | 18 | 0.230 |
Why?
|
| Methotrexate | 1 | 2025 | 80 | 0.230 |
Why?
|
| Precision Medicine | 2 | 2023 | 118 | 0.220 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 921 | 0.220 |
Why?
|
| Genes, Reporter | 3 | 2019 | 257 | 0.220 |
Why?
|
| Lysosomes | 4 | 2025 | 166 | 0.220 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2023 | 5 | 0.210 |
Why?
|
| Blood-Brain Barrier | 2 | 2025 | 85 | 0.210 |
Why?
|
| Skin Abnormalities | 1 | 2023 | 8 | 0.210 |
Why?
|
| Neuroimaging | 1 | 2024 | 153 | 0.200 |
Why?
|
| Anticonvulsants | 2 | 2022 | 107 | 0.190 |
Why?
|
| Catheters | 2 | 2019 | 74 | 0.190 |
Why?
|
| Homeostasis | 1 | 2025 | 369 | 0.190 |
Why?
|
| Mutant Proteins | 1 | 2022 | 105 | 0.180 |
Why?
|
| Huntingtin Protein | 2 | 2019 | 143 | 0.180 |
Why?
|
| Mutation | 4 | 2023 | 2608 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 23 | 0.170 |
Why?
|
| C9orf72 Protein | 1 | 2021 | 114 | 0.170 |
Why?
|
| Growth Plate | 1 | 2020 | 9 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 149 | 0.160 |
Why?
|
| Antigens, Ly | 1 | 2019 | 42 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2020 | 76 | 0.160 |
Why?
|
| Injections, Spinal | 1 | 2019 | 46 | 0.160 |
Why?
|
| Cryotherapy | 1 | 2019 | 16 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2020 | 220 | 0.160 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.160 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 58 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2020 | 144 | 0.150 |
Why?
|
| Male | 10 | 2025 | 29897 | 0.150 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 262 | 0.150 |
Why?
|
| Video Recording | 1 | 2019 | 135 | 0.150 |
Why?
|
| Animals, Genetically Modified | 1 | 2020 | 290 | 0.150 |
Why?
|
| Models, Animal | 1 | 2019 | 236 | 0.150 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2019 | 86 | 0.150 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 653 | 0.140 |
Why?
|
| Microglia | 2 | 2017 | 242 | 0.140 |
Why?
|
| Hypocalcemia | 1 | 2017 | 19 | 0.130 |
Why?
|
| Mice | 8 | 2025 | 10833 | 0.130 |
Why?
|
| G(M2) Ganglioside | 3 | 2024 | 10 | 0.130 |
Why?
|
| Electroencephalography | 1 | 2017 | 149 | 0.120 |
Why?
|
| beta-Galactosidase | 3 | 2023 | 77 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 294 | 0.120 |
Why?
|
| Disease Progression | 5 | 2025 | 1171 | 0.120 |
Why?
|
| Viral Tropism | 1 | 2016 | 51 | 0.120 |
Why?
|
| Animal Structures | 1 | 2015 | 5 | 0.120 |
Why?
|
| Mucopolysaccharidoses | 1 | 2015 | 4 | 0.120 |
Why?
|
| Muscles | 1 | 2016 | 179 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2019 | 419 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 127 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2022 | 792 | 0.110 |
Why?
|
| Echocardiography | 1 | 2017 | 500 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2019 | 894 | 0.110 |
Why?
|
| Gangliosides | 3 | 2022 | 18 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 266 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 107 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1616 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 574 | 0.090 |
Why?
|
| Drug Administration Routes | 2 | 2021 | 21 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 1644 | 0.090 |
Why?
|
| Injections, Intraventricular | 2 | 2025 | 21 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5680 | 0.090 |
Why?
|
| Child | 3 | 2025 | 4534 | 0.080 |
Why?
|
| Primates | 2 | 2021 | 51 | 0.080 |
Why?
|
| Infant | 2 | 2025 | 1650 | 0.080 |
Why?
|
| Stroke | 1 | 2019 | 1198 | 0.080 |
Why?
|
| Female | 5 | 2025 | 32875 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2025 | 1997 | 0.080 |
Why?
|
| Astrocytes | 2 | 2020 | 119 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1275 | 0.070 |
Why?
|
| Aged | 1 | 2022 | 14436 | 0.060 |
Why?
|
| Infusions, Intraventricular | 1 | 2025 | 12 | 0.060 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2024 | 10 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 83 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1537 | 0.060 |
Why?
|
| Cattle | 1 | 2025 | 308 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2024 | 57 | 0.050 |
Why?
|
| Adolescent | 2 | 2025 | 6251 | 0.050 |
Why?
|
| Collagen Type V | 1 | 2023 | 2 | 0.050 |
Why?
|
| Neurons | 2 | 2021 | 922 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 44 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2023 | 81 | 0.050 |
Why?
|
| Collagen | 1 | 2023 | 123 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 131 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 147 | 0.050 |
Why?
|
| G(M1) Ganglioside | 1 | 2022 | 7 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 42 | 0.050 |
Why?
|
| Motor Activity | 1 | 2024 | 346 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 1228 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 89 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1122 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 89 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 25 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 81 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2021 | 232 | 0.040 |
Why?
|
| Liver | 1 | 2025 | 855 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2020 | 8 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2020 | 64 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 390 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 276 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 80 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 75 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 313 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 147 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 39 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 161 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 334 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 114 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 68 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 375 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 175 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 232 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 369 | 0.040 |
Why?
|
| Dogs | 1 | 2019 | 325 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 665 | 0.030 |
Why?
|
| Gliosis | 1 | 2016 | 28 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2016 | 37 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 719 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1001 | 0.030 |
Why?
|
| Cricetulus | 1 | 2015 | 99 | 0.030 |
Why?
|
| CHO Cells | 1 | 2015 | 188 | 0.030 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cerebrosides | 1 | 2015 | 3 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 517 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 40 | 0.030 |
Why?
|
| Young Adult | 1 | 2025 | 4692 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 896 | 0.030 |
Why?
|
| Breeding | 1 | 2014 | 26 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 489 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 204 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 429 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 242 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 195 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 779 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 582 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 1148 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3290 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2038 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1552 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7842 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1512 | 0.020 |
Why?
|
| Adult | 1 | 2025 | 16826 | 0.020 |
Why?
|